

# Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter

The International Journal of Biological  
Markers

2021, Vol. 36(1) 54–61

© The Author(s) 2021


Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/1724600821996372

journals.sagepub.com/home/ijbm



Brian I. Carr<sup>1</sup> , Vito Guerra<sup>2</sup>, Rossella Donghia<sup>2</sup>, Fabio Farinati<sup>3</sup>,  
Edoardo G. Giannini<sup>4</sup>, Fabio Piscaglia<sup>5</sup>, Gian Ludovico Rapaccini<sup>6</sup>,  
Maria Di Marco<sup>7</sup>, Eugenio Caturelli<sup>8</sup>, Marco Zoli<sup>9</sup>, Rodolfo Sacco<sup>10</sup>,  
Giuseppe Cabibbo<sup>11</sup>, Fabio Marra<sup>12</sup>, Andrea Mega<sup>13</sup>,  
Filomena Morisco<sup>14</sup>, Antonio Gasbarrini<sup>15</sup>,  
Gianluca Svegliati-Baroni<sup>16</sup>, Francesco Giuseppe Foschi<sup>17</sup>,  
Gabriele Missale<sup>18</sup>, Alberto Masotto<sup>19</sup>, Gerardo Nardone<sup>20</sup>,  
Giovanni Raimondo<sup>21</sup>, Francesco Azzaroli<sup>22</sup>, Gianpaolo Vidili<sup>23</sup>,  
Filippo Oliveri<sup>24</sup> and Franco Trevisani<sup>25</sup>

## Abstract

**Background:** Hepatocellular carcinoma prognosis depends on both liver and tumor determinants, especially on maximum tumor diameter, multifocality, and presence of portal vein thrombosis, despite apparently complete tumor removal by resection or liver transplantation.

<sup>1</sup>Inonu University, Liver Transplant Institute, Malatya, Turkey

<sup>2</sup>National Institute of Digestive Diseases. IRCCS S. de Bellis Research Hospital, Castellana Grotte, Italy

<sup>3</sup>Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy

<sup>4</sup>Department of Internal Medicine, Gastroenterology Unit, University of Genova, IRCCS Policlinico San Martino, Genova, Italy

<sup>5</sup>Azienda Ospedaliero-Universitaria S. Orsola-Malpighi, Internal Medicine–Piscaglia Unit, Bologna, Italy

<sup>6</sup>Gastroenterology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy

<sup>7</sup>Medicine Unit, Bolognini Hospital, Seriate, Italy

<sup>8</sup>Gastroenterology Unit, Belcolle Hospital, Viterbo, Italy

<sup>9</sup>Department of Medical and Surgical Sciences, Internal Medicine–Zoli Unit, Alma Mater Studiorum – University of Bologna, Bologna, Italy

<sup>10</sup>Gastroenterology and Digestive Endoscopy Unit, Foggia University Hospital, Foggia, Italy

<sup>11</sup>Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, PROMISE, Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy

<sup>12</sup>Department of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Firenze, Firenze, Italy

<sup>13</sup>Gastroenterology Unit, Bolzano Regional Hospital, Bolzano, Italy

<sup>14</sup>Department of Clinical Medicine and Surgery, Gastroenterology Unit, University of Napoli “Federico II”, Napoli, Italy

<sup>15</sup>Internal Medicine and Gastroenterology Unit, Policlinico Gemelli, Università Cattolica del Sacro Cuore, Roma, Italy

<sup>16</sup>Gastroenterology Unit, Polytechnic University of Marche, Ancona, Italy

<sup>17</sup>Department of Internal Medicine, Ospedale per gli Infermi di Faenza, Faenza, Italy

<sup>18</sup>Infectious Diseases and Hepatology Unit, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy

<sup>19</sup>Gastroenterology Unit, Sacred Heart hospital, Negrar, Italy

<sup>20</sup>Department of Clinical Medicine and Surgery, Hepato-Gastroenterology Unit, University of Napoli “Federico II”, Napoli, Italy

<sup>21</sup>Department of Clinical and Experimental Medicine, Clinical and Molecular Hepatology Unit, University of Messina, Messina, Italy

<sup>22</sup>Department of Surgical and Medical Sciences, Gastroenterology Unit, Alma Mater Studiorum – University of Bologna, Bologna, Italy

<sup>23</sup>Department of Medical, Surgical and Experimental Sciences. Clinica Medica Unit, University of Sassari, Azienda Ospedaliero-Universitaria of Sassari, Sassari, Italy

<sup>24</sup>Department of Clinical and Experimental Medicine, Hepatology and Liver Physiopathology Laboratory and Internal Medicine, University of Pisa, Pisa, Italy

<sup>25</sup>Department of Medical and Surgical Sciences, Semeiotics Unit, Alma Mater Studiorum – University of Bologna, Bologna, Italy

## Corresponding author:

Brian I. Carr, Liver Transplant Institute, Inonu University, Bulgurlu Mah, Elazig Yolu 10 km, #44210, 44000 Battalgazi, Malatya, 44280, Turkey.  
Email: brianicarr@hotmail.com



**Aims:** To examine parameters of hepatocellular carcinoma aggressiveness as tumor size increases.

**Methods:** A large hepatocellular carcinoma database was examined for trends in serum alpha-fetoprotein and the percentage of patients with macroscopic portal vein thrombosis or tumor multifocality.

**Results:** A total of 13,016 hepatocellular carcinoma patients were identified having full tumor and survival data. Of these, 76.56% were male and 23.44% were female, with a median age of 64.4 years. We found that as the maximum tumor diameter increased, there was a significant trend for increased alpha-fetoprotein levels ( $P < 0.001$ ) and an increased percentage of patients with either portal vein thrombosis or tumor multifocality, each  $P < 0.0001$ . Furthermore, the increases of both alpha-fetoprotein and portal vein thrombosis were proportionately greater than the related maximum tumor diameter increases. These trends of increased alpha-fetoprotein, portal vein thrombosis, and multifocality with increasing maximum tumor diameter had non-linear patterns. Within alpha-fetoprotein and multifocality trends, there were identifiable sub-trends associated with specific maximum tumor diameter ranges.

**Conclusions:** The greater fold-increases in alpha-fetoprotein and portal vein thrombosis compared with increases in maximum tumor diameter imply that hepatocellular carcinoma characteristics may change with increasing size to a more aggressive phenotype, suggesting that follow-up tumor sampling might be useful, in addition to baseline tumor sampling, for optimal therapeutic choices to be made.

## Keywords

HCC, size, trend, evolution

Date received: 13 November 2020; revised: 28 January 2021; accepted: 1 February 2021

## Introduction

The concept that a 5 cm maximum tumor diameter (MTD) might represent a watershed for liver transplant for single hepatocellular carcinoma (HCC) lesions, after which recurrence rates increased, was introduced with the Milan criteria<sup>1</sup> and has generally withstood the test of time. Subsequently, small MTD increases were also shown to be compatible with prolonged post-transplant survival.<sup>2-4</sup> However, it has never been clear how these unchallenged size guidelines could be explained by tumor biology, since at transplant both the tumor and non-tumor underlying liver are removed. Furthermore, although increase in tumor size has been known to be an adverse prognostic factor, it has recently been suggested that size alone may not be so important, but rather other factors may be more important and that these factors might change with increase in MTD, which could explain the relevance of increasing MTD to worse prognosis.<sup>2,4</sup> The current study was motivated by the desire to know whether HCC biology, as expressed in tumor factors alpha-fetoprotein (AFP), macroscopic portal vein invasion (PVT), or tumor multi-nodularity/multifocality in addition to MTD, which are all known HCC adverse prognosis factors,<sup>5-8</sup> might change with increase in MTD.

## Methods

### Clinical data collection

We analyzed prospectively collected data in the Italian Liver Cancer (ITA.LI.CA) study group database of 13,016 HCC patients accrued until 2018 at collaborating Italian centers, with full baseline tumor parameter data, including computed tomography scan information on MTD, the

number of tumor nodules, the presence or absence of PVT and serum AFP levels; plus complete blood counts; routine blood liver function tests, (total bilirubin, gamma glutamyltranspeptidase (GGTP), alkaline phosphatase (ALKP), albumin, aspartate aminotransaminase (AST), alanine transaminase (ALT); demographics and survival information, as previously reported.<sup>9</sup>

**Ethics.** The ITA.LI.CA database management is compliant with the current Italian legislation on privacy, and the study conforms to the ethical guidelines of the Declaration of Helsinki. All patients provided informed consent to having their data entered into the ITA.LI.CA database with an anonymized identification number. The study design was approved (protocol n. 99/2012/O/Oss) by the Independent Ethic Committee of S. Orsola-Malpighi hospital of Bologna, that operates as coordinating center of the ITA.LI.CA network. In all the remaining centers, data inclusion into ITA.LI.CA registry was approved by the local ethics committees.

### Statistical analysis

Patient characteristics were reported as mean  $\pm$  SD ( $M \pm SD$ ) or as median for continuous variables, and as frequencies and percentages for categorical variables.

Normal distributions of quantitative variables were tested using the Kolmogorov-Smirnov test.

For testing the associations between groups, the Chi-square test for categorical variables was used; when the variables were not distributed normally, the Kruskal-Wallis rank test was used for continuous variables.

The  $\chi^2$  method for trend was performed to evaluate the trend between categorical levels for PVT positive

**Table 1.** Clinical and tumor parameter values subdivided by MTD categories.

Parameter	MTD (cm)				P*	P <sup>§</sup>
	≤2.0 (n=3184)	(2.1–5.0) (n=6373)	(5.1–8.0) (n=2035)	(8.1–11.0) (n=1424)		
PVT (yes) (%)	139 (6.24)	606 (13.69)	526 (33.44)	702 (58.06)	<0.001 <sup>^</sup>	<0.0001
Nodules number (number)						
Multifocality (n>2) (%)	222 (7.15)	711 (11.42)	541 (27.67)	708 (51.94)	<0.001 <sup>^</sup>	<0.0001
AFP (IU/mL) median (min–max)	11.4 (0.50–1,133,400)	17.04 (0.13–2,203,900)	90.00 (0.50–726,494)	394 (0.90–1,962,333)	0.0001	<0.001
Total Bilirubin (mg/dL) median (min–max)	1.01 (0.06–38)	1.10 (0.8–50)	1.10 (0.1–310)	1.13 (0.12–33)	0.0001	<0.001
Platelet counts (10 <sup>3</sup> /μL) median (min–max)	107.00 (8–396,000)	115.00 (7–423,000)	142.00 (8–358,000)	185.00 (28–2,700,000)	0.0001	<0.001
ALKP (U/L) median (min–max)	220.00 (22–130,900)	220.00 (6.6–203,500)	220.00 (16–258,500)	231.50 (34–163,900)	0.0001	0.096
GGTP (U/L) median (min–max)	136.00 (3–137,500)	140.00 (1–112,400)	170.00 (4–44,100)	200.00 (3.9–86500)	0.0001	<0.001
Hemoglobin (g/dL) median (min–max)	13.00 (5–18.6)	12.90 (3.1–158)	12.70 (5.2–32.4)	12.30 (3.1–19.6)	0.0001	<0.001
ALT (U/L) median (min–max)	48.00 (3.6–69,800)	48.00 (3.6–69,800)	51.00 (5.2–26,360)	55.00 (3–7640)	0.05	0.095
AST (U/L) median (min–max)	57.20 (6.8–16,320)	58.00 (2.4–10,960)	65.00 (10.8–19,680)	82.00 (10–9720)	0.0001	<0.001
Albumin (g/dL) median (min–max)	3.60 (0.3–46)	3.51 (0.6–47)	3.50 (0.33–23)	3.30 (0.23–27)	0.0001	<0.001

AFP: alpha-fetoprotein; ALKP: alkaline phosphatase; ALT: alanine transaminase; AST: aspartate aminotransaminase; GGTP: gamma glutamyltranspeptidase; MTD: maximum tumor diameter; PVT: portal vein thrombosis.

\*Kruskal-Wallis rank test; <sup>^</sup>chi-square test; <sup>§</sup>test for trend.

(PVT(+)) and multifocality (>2). For continuous variable AFP (median), the non-parametric test for trend across ordered groups was used.

The proportion test was applied to evaluate the statistical differences between the parameters as category for each level of ordered MTD (cm).

To evaluate the variation in the increase for the median of AFP or the percentage of PVT(+) and multifocality, the equation of the interpolating line for each modification of variation of the increase was used.

The variation of medians of AFP, percentage of PVT(+) and percentage of multifocality (n>2) in relation to the increase of MTD was calculated both as a percentage variation from the previous value of parameters analyzed as increase in tumor size compared to the reference band. This proportionality factor represents how many times the value of the single factor increased with increasing MTD compared to the first category of MTD.

When testing the null hypothesis of no association, the probability level of error at two tails was 0.05. All the statistical computations were made using STATA, StataCorp. 2019. *Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC.

## Results


### Clinical characteristics of increasing MTD groups

Patient clinical characteristics were grouped according to 3 cm increases in MTD, with a central point of ≤5 cm or >5 cm (Table 1a). The tumor characteristics of the percentage of patients with PVT, the percentage of patients with tumor multifocality, and the median serum AFP levels all increased with the increase in MTD categories. The increase was most profound for the transition from MTD 2.1–5.0 cm to MTD 5.1–8 cm, being 13.09% of patients with PVT versus 33.44% of patients with (2.55-fold increase); and was 11.42% of patients with multifocality versus 27.67% of patients with PVT (2.42-fold increase); and was a median serum AFP of 17.04 versus 90.0 IU/mL (5.28-fold increase).

The increases of all the blood parameters were significant except for ALKP and ALT, although white blood cell count, hemoglobin (Hb) and albumin had decreases with increasing MTD (for albumin, this reflected a worsening in inflammatory response.<sup>10-12</sup> The maximum increase in parameter from smallest to largest MTD was for GGTP, which did not reach a doubling (a two-fold increase).

### Serum AFP trends in relation to increases in MTD

To examine the tumor parameters in relation to MTD in more detail, the levels of serum AFP were plotted according to 1 cm MTD increments, and significant



**Figure 1.** Trends in serum AFP levels in relationship to MTD. AFP: alpha-fetoprotein; MTD: maximum tumor diameter.

increases were seen in AFP levels as MTD increased (Figure 1(a)). Examination of the results in Figure 1(a) suggested three components to the graph, which were then analyzed separately as shown in Figure 1(b), together with the equations for their interpolation lines. From MTD  $\leq 2$  cm to 4.1–5.0 cm there was a very weak AFP increase, followed by a moderate increase or variation from MTD 4.1–5.0 cm to 6.1–7.0 cm, and then a strong increase from MTD 6.1–7.0 cm to 7.1–8 cm. We attempted to quantitate the changes for each point in Figure 1(a) with respect to each previous point, as shown in the histogram in Figure 1(c), demonstrating the percentage variation of each point in comparison with its predecessor point.

### *Trends in percentage of patients with tumor multifocality or PVT in relation to MTD increases*

The percentage of patients with tumor multifocality were then plotted according to 1 cm MTD increments, and a significant increase was found in the percentage of patients with multifocality as MTD increased (Figure 2(a)). The graph was also non-linear as found for AFP, and sub-trends were identified as shown in Figure 2(b), with the equation of the interpolation line each being depicted next to each sub-trend. A similar approach was taken with respect to the percentage of patients with PVT (Figure 2(c)), which were also significantly associated with increases in MTD. Furthermore, a significant trend was also found for the percentage of PVT in patients with low serum AFP ( $< 100$  IU/mL) levels, as shown in Figure 2(c<sub>1</sub>) (inset to Figure 2(c)).


### *Variation of AFP, percentage of patients with PVT or multifocality in relation to MTD changes*

We then approached the extent of the changes in each of the three tumor parameters, namely AFP levels, rate of PVT (%) or rate of multifocality (%) in relation to the extent of the MTD changes (Table 2), as we tried to determine if the increase in each parameter was just proportional to the increase in MTD and thus reflective of the tumor amount, or more than proportional and thus indicative of a change in tumor biology with an increase in tumor size.

We found that for median AFP levels and the rate of PVT, the increase in parameter value was greater than the MTD increase. However, the rate of multifocality increased in proportion to the MTD increases. These findings support the idea that as the tumor size increased, the tumor parameter increased by an even greater amount (for AFP and PVT, but not for multifocality), supporting the hypothesis that the HCC biology became more aggressive with the increase in MTD.

## **Discussion**

The motivation for this study was the apparent “barrier” around 5 cm for long survival post liver transplant for HCC. HCC recurrences post resection or ablation can be explained as due to local invasion or second malignancies when the predisposing cause (inflammation, cirrhosis, hepatitis, alcohol, etc.) continues. However, after transplant, the predisposing liver (but not the systemic) milieu has been removed. An obvious explanation for post-transplant recurrences is that, like other malignancies, there may be circulating micro-metastases that can seed the new liver after removal of the primary tumor (cf. breast, lung,



**Figure 2.** Trends in tumor multifocality (>2) (% patients) in relation to MTD. MTD: maximum tumor diameter.

colorectal cancers). Doubtless this could occur for HCC, especially under the influence of residual circulating hepatitis virions plus immunosuppression. This work was not intended to study liver transplant, but to enquire whether there might be a general change in HCC phenotype as the tumor grows, which could explain the high recurrences post ablative or transplant therapies, when performed for larger HCCs.

When this large cohort of HCC patients was ordered by increase in MTD, we found that there was an increase in the three parameters of AFP, the rate of PVT and the rate of multifocality with increasing MTD (itself an HCC aggressiveness parameter<sup>13</sup>). This may be unsurprising, as with each doubling in MTD, there is a doubling or more (tumor volume is  $4/3 \pi r^3$ ) in tumor mass. However, inspection of

the graphs for AFP and the rate of multifocality (Figures 1(a) and 2(a)) suggest that there are two striking findings. First, there is more than a single component to each graph, as analyzed in Figures 1(b) and 2(b) (although this possibility is less clear for % PVT, in Figure 2(c)). Second, when the fold-increases (proportionality) were then calculated for each parameter with respect to the MTD fold-increases (Table 2), we found that for AFP and the rate of PVT (but less so for % multifocality), the parameter fold-increases exceeded the MTD fold-increases.

These results suggest that the parameter increases were not linear or in proportion to the MTD increases, but were greater, and might be explained by a change in HCC phenotype with the increase in tumor size. This hypothesis could be more formally tested in the future by examination of the



**Table 2.** Variation of AFP, PVT(+), and multifocality (n>2) in relationship to maximum tumor diameter in categories in HCC patients.

Interval MTD (cm)	N	Increase* MTD (cm)	AFP (Median) (min-max)	Proportionality factor from first median value	PVT(+) (%)	Proportionality factor from first percentage value	Multifocality (n>2) (%)	Proportionality factor from first percentage value
(≤4.0)	4235	Ref.	13.00 (0.13–220.3900)	–	530 (9.34)	–	725 (9.01)	–
(4.1–6.0)	1181	2	40.30 (0.5–726.494)	3.10	397 (24.36)	2.61	411 (19.59)	2.17
(4.1–8.0)	2357	4	59.90 (0.5–726.494)	4.61	741 (29.04)	3.11	749 (23.12)	2.57
(4.1–10.0)	2278	6	75.90 (0.5–135.1100)	5.84	1103 (33.54)	3.59	1066 (25.91)	2.88
(4.1–12.0)	2018	8	99.00 (0.5–196.2333)	7.62	1551 (39.00)	4.18	1580 (32.71)	3.63

AFP: Alpha-fetoprotein; MTD: maximum tumor diameter; PVT: portal vein thrombosis.

It is the proportionality factor that relates the value of the AFP, PVT(+), and multifocality (n>2) respectively, and corresponding to the category of tumor size, with respect to the value referred to the first category of MTD.

This proportionality factor represents how many times the value of AFP, PVT(+), and multifocality (n>2) respectively, increases with increasing tumor size (MTD), compared to the first category of MTD (≤4.0 cm).

\*Increase in tumor size compared to the reference width.

baseline tumor biopsy in comparison with the explanted HCC material, for tumor mutation burden, microsatellite instability, or other measures of change in HCC biology, including growth factor receptors and programmed cell death-1-receptors. Of course, the data from Figures 1(a), 2(a), and 2(c) also show that the HCC patients are heterogeneous, since there are still many patients with low serum AFP (median values are shown) and with both a low rate of multifocality and a low rate of PVT.

Interestingly, the examination of trends for several blood count and liver parameters (Table 1), suggests changing trends for more than one parameter. Thus, the Hb trend downwards with the increase in MTD is possibly associated with systemic inflammation, yet blood platelets trend upwards, as has been documented previously for larger sized HCCs.<sup>9,14</sup> AST trends upwards with increasing MTD, consistent with increased inflammation, as well as GGTP, which may also reflect hepatic inflammation, but is additionally reported as a candidate HCC biomarker.<sup>15,16</sup> Similarly, albumin trends downwards with increasing MTD, consistent with it being an inflammation biomarker.<sup>10,12</sup> Major increases in serum AFP, the rate of PVT and the rate of multifocality were found around a 5 cm MTD pivot point.

Changes in solid human tumors during disease management have been reported for decades, especially in breast and colon cancer, when resistance can develop to cancer chemotherapy treatments over time. However, the changes reported here, which are associated with the increase in MTD, do not seem to be induced by a clear cause. However, there is considerable literature in rodent hepatocarcinogenesis studies on the induction by multiple hepatotoxic chemicals and hepatocarcinogens of resistance to subsequent challenge by a variety of unrelated hepatotoxins, as well as to the chemotherapeutic agent doxorubicin.<sup>17-21</sup> Thus it is possible that the well-described pleiotropic drug resistance of experimental chemical hepatocarcinogenesis may have its clinical counterpart in the predominantly cancer chemotherapeutic resistance of most human HCC.

HCC aggressiveness factors of PVT, AFP, or multifocality have been previously shown to correlate with the increase in tumor size or MTD.<sup>22-27</sup> Whether this is causal or mere association has not been clarified. The two most likely hypotheses to explain the relation of size to other aggressiveness factors are the probability of aggressiveness factors per increased unit of tumor size versus an increased tumor size producing more factors that stimulate tumor invasiveness.

Therefore, a partial answer to the initial enigma of a 5 cm threshold for HCCs in liver transplant may be that other aggressiveness factors—such as AFP, PVT, and multifocality—increase in tandem with the increase in MTD. Thus, it is not the MTD alone that is increasing the probability of post-transplant recurrence, but rather the total aggressiveness profile that is a part of the increasing MTD.

An implication of these findings is an apparent change in HCC tumor biology with the increase in MTD. If

correct, then a single baseline tumor biopsy at diagnosis might be insufficient for rational therapeutic decision making during the months of disease progression. Additional biopsies over the disease course might then be reasonable. However, since they are invasive procedures, liquid biopsy through repeated blood sampling might have a major advantage in this setting, especially when uniformity of the various liquid biopsy platforms has been established. Liquid biopsy for analysis of the analytes circulating tumor cells, circulating tumor RNA, or for genetic alterations in cell free tumor DNA in the bloodstream, is moving from experimental to practical clinical application in many solid tumors, including HCC, both for tumor typing,<sup>28-30</sup> for early detection in patients at risk, and with small tumors<sup>31</sup>; for the prediction of drug responsiveness, such as for the detection of the epidermal growth factor receptor and P13K3CA mutations.<sup>32</sup> Plasma cell-free DNA-based epigenomics tests, such as for DNA methylation,<sup>33</sup> are starting to head to market, by companies such as Helio, Guardant (FDA-approved Guardant360 CDx test), NeoGenomics, Ivygene Dx Liver Cancer test, as well as several others.

Furthermore, some clinically approved tests, such as positron emission tomography imaging, based on the uptake of <sup>18</sup>fluorodeoxyglucose into metabolically active HCCs, has begun to attract interest due to its ability to predict survival, portal venous invasion, and degree of HCC differentiation.<sup>34-36</sup>

The findings reported here suggest a change in HCC biology with tumor growth and imply the need for sequential tumor sampling during the months of patient care and treatments.

## Conclusions

We found that as MTD increased, so did median serum AFP levels, as well as the percentage of patients with both PVT and multifocality, but in a non-linear manner and to a greater extent than the increase in MTD. These findings suggest that HCC aggressiveness might worsen or evolve with tumor growth. Multiple—perhaps liquid—biopsies might thus better inform treatment decisions as the tumor grows, rather than a single biopsy at baseline.

## Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported in part by NIH grant CA 82723 (B.I.C.).

## ORCID iD

Brian I. Carr  <https://orcid.org/0000-0002-6111-5077>

## References

- Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; 334: 693–699.
- Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. *Hepatology* 2001; 33: 1394–1403.
- Llovet JM, Pavel M, Rimola J, et al. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). *Liver Transplant* 2018; 24: 369–379.
- Ince V, Akbulut S, Otan E, et al. Liver transplantation for hepatocellular carcinoma: Malatya experience and proposals for expanded criteria. *J Gastrointest Cancer* 2020; 51: 998–1005.
- Spreafico C, Sposito C, Vaiani M, et al. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. *J Hepatol* 2018; 68: 724–732.
- Kim N and You MW. Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. *Jpn J Radiol* 2019; 37: 781–792.
- Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. *Cancer* 2004; 101: 796–802.
- Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. *Cancer* 1985; 56: 918–928.
- Carr BI, Guerra V, Giannini EG, et al. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. Italian Liver Cancer Group. *Int J Biol Markers* 2014; 29: e215–e223.
- Arroyo V, García-Martínez R and Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. *J Hepatol* 2014; 61: 396–407.
- Carr BI, Guerra V, Giannini EG, et al. A liver index and its relationship to indices of HCC aggressiveness. *J Integr Oncol* 2016; 5: 178.
- Pinato DJ, Stebbing J, Ishizuka M, et al. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation-based index (IBI). *J Hepatol* 2012; 57: 1013–1020.
- Carr BI and Guerra V. A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. *Oncology* 2016; 90: 215–220.
- Carr BI and Guerra V. Hepatocellular carcinoma size: platelets,  $\gamma$ -glutamyl transpeptidase, and alkaline phosphatase. *Oncology* 2013; 85: 153–159.
- Sun P, Li Y, Chang L, et al. Prognostic and clinicopathological significance of gamma-glutamyltransferase in patients with hepatocellular carcinoma: A PRISMA-compliant meta-analysis. *Medicine (Baltimore)* 2019; 98: e15603.
- Ince V, Carr BI, Bag HG, et al. Gamma glutamyltranspeptidase as a prognostic biomarker in hepatocellular cancer patients especially with >5 cm tumors, treated by liver transplantation. *Int J Biol Markers* 2020; 35: 91–95.

17. de M MacNider W. The resistance of liver epithelium to injury by uranium following chloroform exposure. *J Pharm Expt Ther* 1936; 56: 373.
18. Haddow A. Cellular inhibition and the origin of cancer. *Acta Unio Int Contra Cancrum* 1938; 3: 342–352.
19. Farber E, Parker S and Gruenstein M. The resistance of putative pre-malignant liver cell populations to the acute cytotoxicity of hepatocarcinogens. *Cancer Res* 1976; 36: 3879.
20. Carr BI and Laishes BA. Carcinogen-induced drug resistance in hepatocytes. *Cancer Res.* 1981; 41: 1715.
21. Carr BI and Laishes BA. Resistance to the cytotoxic effects of Adriamycin is an early phenotypic change induced during hepatocarcinogenesis. *Br J Cancer* 1981; 44: 567–571.
22. Carr BI and Guerra V. Hepatocellular carcinoma extrahepatic metastasis in relation to tumor size and alkaline phosphatase levels. *Oncology* 2016; 90: 136–142.
23. Carr BI, Pancoska P, Giannini EG, et al. Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters. *Semin Oncol.* 2014; 41: 406–414.
24. Carr BI, Guerra V, Donghia R, et al. Trends in tumor indices in relation to increased hepatocellular carcinoma size: evidence for tumor evolution as a function of growth. *J Gastrointest Cancer* 2020; 51: 1215–1219.
25. Akkiz H, Carr BI, Kuran S, et al. Macroscopic portal vein thrombosis in HCC patients. *Can J Gastroenterol Hepatol* 2018; 2018: 3120185.
26. Pawlik TM, Delman KA, Vuathey JN, et al. Tumor size predicts vascular invasion and histological grade: implications for selection of surgical treatment for hepatocellular carcinoma. *Liver Transpl.* 2005; 11:1086–1092.
27. Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, et al. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. *Hepatology* 2018; 67: 1784–1796.
28. Bettgowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med* 2014; 6:224ra24.
29. Ikeda S, Tsigelny IF, Skjervek AA, et al. next generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma. *Oncologist* 2018; 23: 586–593.
30. Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. *Cancer Discov* 2017; 7:1394–1403.
31. Qu C, Wang Y, Wang P, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. *Proc Natl Acad Sci U S A* 2019; 116: 6308–6312.
32. Narayan P, Ghosh S, Philip R, et al. State of the science and future directions for liquid biopsies in drug development. *Oncologist* 2020; 25: 730–732.
33. Oussalah A, Rischer S, Bensenane M, et al. Plassma mSepT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma. *EBiomedicine* 2018; 30: 138–147.
34. Asman Y, Evenson AR, Even-Sapir E, et al. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma (Review). *Liver Transpl* 2015; 21: 572–580.
35. Rhee WJ, Hwang SH, Byun HK, et al. Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-fetoprotein and <sup>18</sup>F-fluoro-2-deoxyglucose positron emission tomography. *Liver Int* 2017; 37: 592–599.
36. Kornberg A, Kupper B, Thrum K, et al. Increased 18F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patients. *Transplant Proc.* 2009; 41: 2561–2563.